Main Industry
Biotechnology
Main Product/Service
Current traditional animal vaccine technologies still primarily rely on live and attenuated vaccines. However, when facing emerging viral diseases (such as swine coronavirus: Porcine Epidemic Diarrhea Virus, PEDV), the protective efficacy of traditional vaccines is extremely limited, and outbreaks often cause devastating economic losses to the swine industry. Currently, there is no safe, effective, and side-effect-free vaccine on the market capable of blocking the chain of viral transmission.
Through the patented technology developed by BacuNova BioTech Co., Ltd.—the baculovirus surface antigen display system—we have successfully constructed a novel baculovirus vaccine that is far more effective than traditional vaccines. Practical application in animal trials has confirmed that it can effectively protect pigs, increase in vivo neutralizing antibody titers, reduce the occurrence of clinical symptoms, and improve the survival rate of pigs.
Funded by the Ministry of Science and Technology, BacuNova BioTech Co., Ltd. is currently commissioning a GMP veterinary biopharmaceutical plant for pilot production and is applying for a vaccine license. Moving forward, we will leverage this technology to develop a wider and more comprehensive range of vaccine products, aiming to tap into the global veterinary vaccine market valued at tens of billions.
Through the patented technology developed by BacuNova BioTech Co., Ltd.—the baculovirus surface antigen display system—we have successfully constructed a novel baculovirus vaccine that is far more effective than traditional vaccines. Practical application in animal trials has confirmed that it can effectively protect pigs, increase in vivo neutralizing antibody titers, reduce the occurrence of clinical symptoms, and improve the survival rate of pigs.
Funded by the Ministry of Science and Technology, BacuNova BioTech Co., Ltd. is currently commissioning a GMP veterinary biopharmaceutical plant for pilot production and is applying for a vaccine license. Moving forward, we will leverage this technology to develop a wider and more comprehensive range of vaccine products, aiming to tap into the global veterinary vaccine market valued at tens of billions.
The content above was translated by Ai
Founded Year
2022
Unified Business No.
90066495
Status
Active
Number of Employees
5
Total Paid-in
Capital
107,000,000 (NT$)
Location of Company
Taiwan
, Taichung City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Led by Dr. Yu-Chan Chao, our company aims to practically apply the scientific research achievements refined over many years to the industrial sector. Dr. Yu-Chan Chao previously served as a Research Fellow at Academia Sinica, with over 30 years of research experience. His primary research focuses on viral pathogenesis mechanisms and the development of vaccines and drugs. During this period, he published a total of more than 80 research journal articles and papers, including in international journals such as *Nature*. He has also received awards such as the National Science Council's Outstanding Research Award three times, the National Science Council's Outstanding Special Contract Researcher Award, and the National Top Ten Outstanding Research Teams Award. In 2022, funded by the National Science and Technology Council's Scientific Research Entrepreneurship Program, he decided to return to his alma mater, National Chung Hsing University, to establish a related spin-off startup. The company focuses on projects such as vaccine development and disease detection, contributing to National Chung Hsing University and Taiwan's biotechnology industry.
The content above was translated by Ai
